MNKD MannKind: Rasio nilai perusahaan marang pendapatan

Logo perusahaan publik MannKind (MNKD)

A steady stream of royalties from pulmonary hypertension treatments strengthens the current cash flow of MannKind Corporation (MNKD). The enterprise value-to-revenue multiple demonstrates the asset's market positioning, where 3893.36 characterizes this valuation parameter. Unique powder inhalers create a significant barrier to entry for competitors, while a lack of dependence on economic cycles due to diabetes therapy ensures the sales stability of Afrezza.

MNKD: Rasio nilai perusahaan marang pendapatan MannKind Corp. 23.11.2025 - 20.11.2026

MNKD (MannKind Corporation): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi saham perusahaan:
- informasi babagan dhuwit lan arus kas:
Pambiji fundamental perusahaan:MannKind, MNKD
Produk asli Afrezza

To assess the long-term risks of MannKind Corporation (MNKD), it is critical to understand the business value relative to its operating income. This indicator compares total market capitalization with net debt and annual revenue to determine the extent of the premium paid for future growth. The current EV/Sales multiple reflects the market's valuation of cash flow generation efficiency. Stable cash inflows and the ability of MannKind Corporation to cover its obligations make this metric a reliable filter for fundamental value.

Pesaing langsung

HLN: Rasio nilai perusahaan marang pendapatan|Kenvue Corp (KVUE) - Rasio nilai perusahaan marang pendapatan|Verona Pharma PLC - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Jyong Biotech Ltd|Multiplikator EV/Sales Ligand Corp|Multiplikator EV/Sales AMRX|Rasio total nilai perusahaan marang pendapatan Perrigo Company plc|Multiplikator EV/Sales ALVO (Alvotech Biopharmaceuticals)|LQDA: Rasio nilai perusahaan marang pendapatan|Galapagos N.V. - Multiplikator EV/Sales|ANIP - Multiplikator EV/Sales|AMPH: Multiplikator EV/Sales|PCRX (Pacira BioSciences) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan ARS Pharmaceuticals Inc|Nilai perusahaan marang pendapatan Theravance Biopharma, Inc. (TBPH)|Nilai perusahaan marang pendapatan AQST (Aquestive Pharma)|SCPH - Multiplikator nilai perusahaan marang pendapatan|Multiplikator EV/Sales TECX (Tectonic Therapeutic, Inc.)|TNXP - Nilai perusahaan marang pendapatan|China SXT Pharmaceuticals, Inc. - Multiplikator EV/Sales|EPRX - Multiplikator EV/Sales|BHST: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan eXoZymes Inc (EXOZ)|ORMP (oramed.com) - Multiplikator EV/Sales|Rasio nilai perusahaan marang pendapatan ENTX (Entera Bio)|Rasio nilai perusahaan marang pendapatan MindWalk (HYFT)|Multiplikator EV/Sales ABVC BioPharma, Inc. (ABVC)|Rasio nilai perusahaan marang pendapatan Cumberland Corp CPIX|QNTM - Nilai perusahaan marang pendapatan|FGEN - Rasio nilai perusahaan marang pendapatan|TELO - Multiplikator EV/Sales|Rani Therapeutics Inc (RANI) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan SNYR|Rasio nilai perusahaan marang pendapatan Rallybio Corp|Rasio nilai perusahaan marang pendapatan LEXX|Multiplikator EV/Sales PULM|PTHL: Nilai perusahaan marang volume dodolan|Multiplikator EV/Sales APM (Aptorum Group Ltd)|LYRA - Nilai perusahaan marang pendapatan|Impact BioMedical Inc - Multiplikator EV/Sales|Nilai perusahaan marang volume dodolan TNFA|YCBD (cbdmd.com) - Nilai perusahaan marang pendapatan|painreform.com - Nilai bisnis marang pendapatan|Nilai perusahaan marang pendapatan CYTO|Rasio nilai perusahaan marang pendapatan LIPO|Rasio nilai perusahaan marang pendapatan optinose.com (OPTN)|PIRS (Pieris Pharma) - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Procaps Group S.A. PROC|Rasio total nilai perusahaan marang pendapatan petrospharma.com (PTPI)|QLI - Rasio nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Rasio nilai perusahaan marang pendapatan